Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Yamamoto

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Cancer Cell|March 4, 2022
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinomaShun Yamamoto, Ken Kato
Expert Opinion on Pharmacotherapy|June 19, 2018
Oral chemotherapy for the treatment of hepatocellular carcinomaShun Yamamoto, Shunsuke Kondo
Clinical Colorectal Cancer|August 29, 2018
Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal CancerNarikazu Boku, Shun Yamamoto
Future Oncology (London, England)|August 12, 2020
Immuno-oncology for esophageal cancerShun Yamamoto, Ken Kato
Expert Opinion on Biological Therapy|July 5, 2020
Pembrolizumab for the treatment of esophageal cancerShun Yamamoto, Ken Kato
Fujita Medical Journal|May 4, 2026
Incidence and risk factors for peripheral intravenous catheter failure in Japanese neonatal intensive care units and growing care units: a multicenter observational studyShun Yamamoto, Ryoko Murayama
Expert Opinion on Biological Therapy|October 21, 2022
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in JapanKentaro Harada, Shun Yamamoto, Ken Kato
Cancer Management and Research|May 17, 2023
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical DataYuntae Kim, Shun Yamamoto, Ken Kato
Future Oncology (London, England)|April 21, 2025
Tislelizumab for the treatment of advanced esophageal squamous cell carcinomaKazuhiro Shiraishi, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety|April 27, 2024
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluationKazumasa Yamamoto, Shun Yamamoto, Ken Kato
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Cancer Cell|March 4, 2022
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinomaShun Yamamoto, Ken Kato
Expert Opinion on Pharmacotherapy|June 19, 2018
Oral chemotherapy for the treatment of hepatocellular carcinomaShun Yamamoto, Shunsuke Kondo
Clinical Colorectal Cancer|August 29, 2018
Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal CancerNarikazu Boku, Shun Yamamoto
Future Oncology (London, England)|August 12, 2020
Immuno-oncology for esophageal cancerShun Yamamoto, Ken Kato
Expert Opinion on Biological Therapy|July 5, 2020
Pembrolizumab for the treatment of esophageal cancerShun Yamamoto, Ken Kato
Fujita Medical Journal|May 4, 2026
Incidence and risk factors for peripheral intravenous catheter failure in Japanese neonatal intensive care units and growing care units: a multicenter observational studyShun Yamamoto, Ryoko Murayama
Expert Opinion on Biological Therapy|October 21, 2022
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in JapanKentaro Harada, Shun Yamamoto, Ken Kato
Cancer Management and Research|May 17, 2023
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical DataYuntae Kim, Shun Yamamoto, Ken Kato
Future Oncology (London, England)|April 21, 2025
Tislelizumab for the treatment of advanced esophageal squamous cell carcinomaKazuhiro Shiraishi, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety|April 27, 2024
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluationKazumasa Yamamoto, Shun Yamamoto, Ken Kato
Pageof 11